SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: DorianGray
Search This Board: 
Last Post: 4/20/2017 12:15:25 PM - Followers: 225 - Board type: Free - Posts Today: 0




Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

Archexin® is a unique anti-sense drug candidate that specifically targets the cancer cell signaling protein Akt-1. Archexin is the only specific inhibitor of Akt-1 in clinical development. The activated form of Akt-1, which is involved in cancer cell growth, survival, angiogenesis, and drug resistance, has been shown to be present or elevated in more than 12 different human cancer cell lines, including pancreatic and renal cell carcinoma. By inhibiting Akt-1, Archexin has shown to inhibit the growth of human renal cell carcinoma cell lines and exhibit a longer survival benefit in the human renal cell carcinoma animal xenograft model. Thus, while Akt-1 is a very specific anti-cancer target, it may have broad therapeutic potential across multiple types of cancer.

RX-3117 is a next generation, orally bioavailable nucleoside analog that is activated (phosphorylated) by the enzyme Uridine Cytidine Kinase 2 (UCK2) and inhibits both DNA and RNA synthesis which induces apoptotic cell death of tumor cells. UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues. This unique specificity for cancer cells may lead to an improved efficacy and safety profile in cancer patients. This profile differs from existing nucleoside compounds (such as the widely used chemotherapy gemcitabine), which are activated by the enzyme DCK which is expressed in both cancer cell and in normal healthy tissue leading to significant toxicities at therapeutic doses. RX-3117 has demonstrated broad spectrum anti-tumor activity against 100 different human cancer cell lines (including Non-Small Cell Lung Cancer (NSCLC), breast, ovarian, pancreas, colon, renal, brain, bladder, cervical) and efficacy in 17 different mouse xenograft models (including colorectal, non-small cell lung, pancreatic and renal cell carcinoma) superior to that of gemcitabine.

Supinoxin (RX-5902) is an orally administered, first-in-class, small molecule inhibitor of phosphorylated-p68 (P-p68). P-p68, which is selectively expressed in cancer cells and is absent in normal tissue, increases the activity of multiple cancer related genes including cyclin D1, c-jun and c-myc, and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been observed in solid tumors, such as melanoma, colon, ovarian and lung.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.


 Rexahn  Pipeline


Management Team

Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University

Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.

Maxim Group, LLC
Echo He, MD, Ph.D.

H. C. Wainwright & Co., LLC
Andrew Fein

Tricia Truehart
(646) 378-2953

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
RNN News: Current Report Filing (8-k) 04/13/2017 04:35:16 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 04/12/2017 05:29:25 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 04/12/2017 05:28:03 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 04/12/2017 05:27:34 PM
RNN News: Statement of Changes in Beneficial Ownership (4) 04/12/2017 05:26:44 PM
#3347  Sticky Note Repost - Updated pipeline chart, as you can DorianGray 03/27/17 11:44:15 PM
#3567   You Think? n3m3sis 04/20/17 12:15:25 PM
#3566   I don't think they're going to waste any Watership 04/19/17 09:00:09 PM
#3565   Probably go up to 0.50 before the R/S. wellfed 04/19/17 05:30:26 PM
#3564   Alrighty then ...? BLUEVOODU 04/19/17 04:25:00 PM
#3563   Yup LongtermLopes 04/19/17 04:20:42 PM
#3562   Care to explain? BLUEVOODU 04/19/17 04:03:19 PM
#3561   Manipulation at its best LongtermLopes 04/19/17 03:08:52 PM
#3560   I bought more today at 39 cents...the r/s shotgun 04/18/17 09:24:28 PM
#3559   Yes... and they look pretty good too. I'm BLUEVOODU 04/18/17 05:45:05 PM
#3558   ERRRRRRRRR!!! There's the 8 second buzzer. AUaft 04/18/17 04:33:15 PM
#3557   $RNN is fortunately not a one trick poney. Cclr0007 04/18/17 04:19:50 PM
#3556   It all depends on what happens after the BLUEVOODU 04/18/17 11:51:09 AM
#3555   Quoted from Seeking Alpha article. BLUEVOODU 04/18/17 11:32:15 AM
#3554   Big manipulation going on here creating panic sales Cclr0007 04/18/17 10:22:50 AM
#3553   They r going to have to release a ttubular 04/17/17 09:05:36 PM
#3552   Agree fully. There's a real opportunity here. Lone Wolf 04/17/17 06:48:31 PM
#3551   The RS is now priced in. They will Cclr0007 04/17/17 05:58:24 PM
#3550   Now 6.9 seconds Cclr0007 04/17/17 05:54:07 PM
#3549   "Investing in early biotechnology companies carries many risks, Theo 04/17/17 02:53:23 PM
#3548   Could Rexahn Pharmaceuticals Have Something? $RNN Woulfe 04/17/17 02:02:17 PM
#3547   I sold because of the RS. Too much cream1996 04/17/17 10:33:16 AM
#3546   Wild ride. Not my first. AUaft 04/17/17 10:22:15 AM
#3545   Good Post!!! n3m3sis 04/15/17 04:49:10 PM
#3544   Good link below that explains why a stock Woulfe 04/15/17 02:44:17 PM
#3543   I am long for RNN, but will it wellfed 04/14/17 07:15:54 PM
#3542   RNN bullish 0.455 stocktrademan 04/14/17 06:23:59 PM
#3541   Ditto!!! and well said that man! n3m3sis 04/14/17 05:27:25 AM
#3540   I will buy more at 39 cents when shotgun 04/13/17 09:56:49 PM
#3539   I didn't see that coming and I don't DorianGray 04/13/17 09:43:15 PM
#3538   What's the bets, is this near bottom or Woulfe 04/13/17 09:04:50 PM
#3537   When the split 1 for 10 is finalized ttubular 04/13/17 06:36:57 PM
#3536   * * $RNN Video Chart 04-13-17 * * ClayTrader 04/13/17 04:26:28 PM
#3535   What did I tell you! Coming back up Beauneedsbiscuits 04/13/17 02:42:29 PM
#3534   I wish it would I would settle for ttubular 04/13/17 02:29:08 PM
#3533   Like this! Lol LongtermLopes 04/13/17 01:53:59 PM
#3532   I liked it better when it was going LongtermLopes 04/13/17 01:51:00 PM
#3531   Dropped 1000$ I'll keep her for a while LongtermLopes 04/13/17 01:49:56 PM
#3530   Excellent buy price. This will yoyo up and Valensio 04/13/17 01:46:47 PM
#3529   I just heard about this thanks to a LongtermLopes 04/13/17 01:45:58 PM
#3528   Right back up as expected. Weak hands folded, Valensio 04/13/17 01:44:10 PM
#3527   This finishes green mark the post LongtermLopes 04/13/17 01:37:49 PM
#3526   Shorts* Valensio 04/13/17 01:34:25 PM
#3525   Bear raid into the .30's. Congrats to the Valensio 04/13/17 01:29:11 PM
#3524   280,000 on the bid above .40......shorts trying to cover... the gipper 04/13/17 01:08:02 PM
#3523   It sounds like they're doing the reverse split Beauneedsbiscuits 04/13/17 12:44:29 PM
#3522   For the time being... expect rough seas. BLUEVOODU 04/13/17 12:38:57 PM
#3521   If a bigger pharma bought... why would they BLUEVOODU 04/13/17 12:34:20 PM
#3520   It's all part of the game. I fuma 04/13/17 12:32:17 PM
#3519   Wow just noticed this stock from reverse split Beauneedsbiscuits 04/13/17 12:12:42 PM
#3518   RNN under Bear Attack. n3m3sis 04/13/17 12:03:14 PM